Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 273

Sort by

Sort Order Select

Journal Articles

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Blood (2025) 146 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2025-4076

Published: 2025

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

Noemie Leblay, Sungwoo Ahn, Alexandra Poos, Mehmet Samur, Sheri Skerget, Holly Lee, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Daniel Penaherrera, Herve Avet-Loiseau, Jonathan Keats, Nikhil Munshi, Niels Weinhold, Nizar Bahlis, Paola Neri

Blood (2025) 146 (Supplement 1): 2163.

https://doi.org/10.1182/blood-2025-2163

Published: 2025

Journal Articles

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Liliana Lucca, Ossama Kohil, Marine Cuisinier, Marie-véronique Joubert, Nadège Carrié, Anaïs Schavgoulidze, Laure Vincent, Xavier Leleu, Benjamin Hebraud, Jill Corre, Aurore Perrot, Herve Avet-Loiseau, Ludovic Martinet

Blood (2025) 146 (Supplement 1): 918.

https://doi.org/10.1182/blood-2025-918

Published: 2025

Journal Articles

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Julie Castiaux, Noemie Bigot, Cyrille Hulin, Magaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Aurore Perrot, Jean-Yves Mary, Jill Corre, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon, Jerome Lambert, Salomon Manier

Blood (2025) 146 (Supplement 1): 498.

https://doi.org/10.1182/blood-2025-498

Published: 2025

Journal Articles

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Blood (2025) 146 (Supplement 1): 493.

https://doi.org/10.1182/blood-2025-493

Published: 2025

Journal Articles

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Blood (2025) 146 (Supplement 1): 1030.

https://doi.org/10.1182/blood-2025-1030

Published: 2025

Journal Articles

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

Mael Penissat-mahaut, Pierre-Paul Axisa, Hélène Daunes, Marine Cuisinier, Marie-véronique Joubert, Céline Mazzotti, Anaïs Schavgoulidze, Stéphane Minvielle, Philippe Moreau, Cyrille Touzeau, Herve Avet-Loiseau, Aurore Perrot, Jill Corre, Ludovic Martinet

Blood (2025) 146 (Supplement 1): 3932.

https://doi.org/10.1182/blood-2025-3932

Published: 2025

Journal Articles

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Blood (2025) 146 (Supplement 1): 367.

https://doi.org/10.1182/blood-2025-367

Published: 2025

Journal Articles

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Blood blood.2025029999.

https://doi.org/10.1182/blood.2025029999

Published: 2025

Includes: Supplemental data

Journal Articles

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jerome Lambert, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean-Marc Schiano, Mourad Tiab, Mohamad Mohty, Frederique Kuhnowski, Jean Fontan, Salomon Manier, Frederique Orsini-Piocelle, Laure Vincent, Sophie Rigaudeau, Xavier Leleu, Benjamin Hebraud, Laurent Flet, Jean-Valere Malfuson, Caroline Jacquet, Driss Chaoui, Nathalie Meuleman, Wajed Abarah, Lydia Montes, Riad Benramdane, Cecile Sonntag, Hacene Zerazhi, Alina Danu, Olivier Allangba, Mamoun Dib, Murielle Roussel, Sophie Cereja, Julien Depaus, Nicolas Branche, Helene Demarquette, Valentine Richez, Brieuc Cherel, Laurent Frenzel, Marie-Christiane Vekemans, Noemie Bigot, Herve Avet-Loiseau, Jill Corre, Philippe Moreau

Blood (2025) 146 (1): 52–61.

https://doi.org/10.1182/blood.2024026230

Published: 2025

Journal Articles

Development of hyperdiploidy starts at an early age and takes a decade to complete

Mehmet K. Samur, Anil Aktas Samur, Parth Shah, Joseph S. Park, Mariateresa Fulciniti, Masood Shammas, Jill Corre, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood (2025) 145 (5): 520–525.

https://doi.org/10.1182/blood.2024025250

Published: 2025

Includes: Supplemental data

Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu

Blood (2024) 144 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2024-210345

Published: 2024

Journal Articles

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Blood (2024) 144 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2024-206867

Published: 2024

Journal Articles

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Anais Schavgoulidze, Mariateresa Fulciniti, Giulia Giorgetti, Sabrina Maheo, Shuhui Deng, Vanessa Favasuli, Srikanth Talluri, Masood A. Shammas, Luka Pavageau, Anil Aktas-Samur, Mehmet K. Samur, Herve Avet-Loiseau, Jill Corre, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 764.

https://doi.org/10.1182/blood-2024-199692

Published: 2024

Journal Articles

Using Single Cell Multi-Omic Clonal Tracking in SMM to Identify Clones That Progress to MM and Harbor Treatment Resistance Features

Adam Sciambi, Daniel Mendoza, Indira Krishnan, Joanne Nguyen, Lubna Nousheen, Benjamin Geller, Cedric Dos Santos, Vivek S. Chopra, Habib Hamidi, Michael Nixon, Yann Nouet, Todd E. Druley, Herve Avet-Loiseau

Blood (2024) 144 (Supplement 1): 4722.

https://doi.org/10.1182/blood-2024-205533

Published: 2024

Journal Articles

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Holly Lee, David Jung, Mansour Poorebrahim, Sacha Benaoudia, Sungwoo Ahn, Noémie Leblay, Eric Letouzé, Philippe Moreau, Herve Avet-Loiseau, Leo Rasche, Jonathan J Keats, Francesco Maura, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 4651.

https://doi.org/10.1182/blood-2024-211833

Published: 2024

Journal Articles

Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study

Michael O'Dwyer, Aideen Edele Ryan, Aoise O'Neill, Catherine Guerin-Charbonnel, Soraya Wuilleme, Jill Corre, Herve Avet Loiseau, Li Peng, Philippe Moreau, Stephane Minvielle

Blood (2024) 144 (Supplement 1): 250.

https://doi.org/10.1182/blood-2024-193955

Published: 2024

Journal Articles

The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 774.

https://doi.org/10.1182/blood-2024-203045

Published: 2024

Journal Articles

Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

Anil Aktas-Samur, Mariateresa Fulciniti, Parth Shah, Sanika Derebail, Raphael E. Szalat, Jill Corre, Kenneth C. Anderson, Giovanni Parmigiani, Herve Avet-Loiseau, Mehmet K. Samur, Nikhil C. Munshi

Blood (2024) 144 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2024-211235

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Identify high-risk disease in multiple myeloma through single-cell transcriptomic detection of highly proliferative (PR) cells

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Circulating tumor cells (CTCs) for dynamic risk assessment of patients (Pts) with smoldering multiple myeloma (SMM)

Antigen-dependent clonal sweep with sequential or combinatory anti-myeloma T cell engagers

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Development of hyperdiploidy starts at an early age and takes a decade to complete

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

PKMYT1 Kinase Is an Actionable Synthetically Lethal Target for Del17p Myeloma

Using Single Cell Multi-Omic Clonal Tracking in SMM to Identify Clones That Progress to MM and Harbor Treatment Resistance Features

BCMA Extracellular Domain Functional Hotspots and Resistance to Variable Anti-BCMA T Cell Engagers in Multiple Myeloma

Increased Expression of the Sialyltransferase Gene ST3GAL1 Predicts Lack of Sustained MRD Negativity and Increased Risk of Progression in Newly Diagnosed, Transplant Eligible Multiple Myeloma Patients in the Maintenance/Observation Phase of Cassiopeia Study

The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only